UBS initiates SpaceX stock coverage with buy rating on Starship potential

UBS initiated coverage of SpaceX with a Buy rating and a $210 price target versus $160.42 (implied upside), valuing the company at ~$2.11T. UBS forecasts SpaceX revenues and EBITDA to compound ~70% and ~90% annually through 2031 to ~$660B and ~$512B, driven by Starship reusability that could cut launch cost per kg to ~$200 from ~$1,000. The news follows SpaceX’s IPO that raised ~$86B (market cap ~ $2.4T) and Fitch’s BBB+ rating for proposed senior unsecured notes tied to repaying a ~$20B bridge loan, but InvestingPro flags the stock as potentially overvalued.

Analysis

The immediate market move is likely more about scarcity and narrative than near-term cash flow. The stock can keep levitating on analyst upgrades, but the valuation now discounts a very steep multi-year execution path, so the asymmetry is better for traders who wait for digestion than for buyers chasing momentum.

The bigger second-order effect is competitive: cheaper launch is not automatically a margin bonanza for the company driving it. In the next 6-18 months, the economic prize may migrate to satellite operators, data distributors, and AI infrastructure users that get lower launch costs without needing to own the rocket factory, while legacy connectivity and launch-adjacent businesses face pricing pressure and customer deferrals.

Near term, the key risks are operational, not macro: a Starship setback, slower launch cadence, or a wider-than-expected debt spread on the new notes would puncture the “inevitable monopoly” narrative. The contrarian miss is that commoditizing access to orbit can compress returns even as volumes grow; if launch gets cheaper faster than pricing power improves, the value capture may be less attractive than the market expects. Falsifiers: a meaningful delay in commercial cadence, EBITDA margins failing to expand with revenue, or credit trading materially wider than high-grade aerospace peers.

Key Decisions for Investors

• Do not chase SPCX into the first post-initiation spike; wait 2-4 weeks for a consolidation or the first secondary/lock-up-related pullback before starting a position. Better entry is a retest of the IPO range with volume drying up; stop if weekly support breaks decisively.
• For risk-tolerant accounts, express the thesis as long SPCX / short TSLA on any overextended 'Musk complex' move over the next 1-3 months. The cleaner asset is the space platform, while TSLA still carries auto-cycle and margin compression risk; this is a relative-value trade, not a directional macro bet.
• Use strength in launch- and satellite-connected incumbents such as IRDM or VSAT as potential shorts or hedges if borrow is available. Thesis horizon: 3-6 months, on the view that lower launch costs pressure incumbent pricing before TAM expansion fully shows up.
• Set alerts on two triggers before adding risk: Starship cadence missing schedule by more than one quarter, or SpaceX notes pricing wider than expected versus BBB+ aerospace credits. Either would argue the market is paying too much for execution certainty.
• No standalone trade in GS or TGT from this note; the signal is too indirect. GS is at most a minor beneficiary of financing activity, not a clean expression of the thesis.